First quarter (2021-07-01 - 2021-09-30)
The Group's net sales amounted to
The Group's loss after financial items amounted to
Result per share amounted to
The solidity as of 2021-09-30 was 94 % (97 %).**
* The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 30th of
** Solidity: Equity divided by total capital.
Highlights during Q1
- July -
ODI Pharma announced that Niclas Kappelin acquired 20,000 shares inODI Pharma and that he thereby exceeded the threshold of five percent. -
August -
ODI Pharma approved the official launch of the exclusive CBD-infused skincare line kandol., which will be available online at www.kandol.net startingmid-September 2021. -
September -
ODI Pharma announced that the official launch date of kandol. will be the 1st ofOctober 2021 . The products will initially be available at www.kandol.net to customers within the EU.
Highlights after the period
- November -
ODI Pharma published its annual report for the fiscal year 2020/2021.
CEO
Our first quarter of the new fiscal year has passed. During these months,
Thanks to extensive research and consumer tests, we see great potential and possible demand for our products. With these promising outcomes, I am proud and confident in continuing to represent
As we have promised our investors, our focus on the release of kandol. is from a financially conservative, step-by-step growth perspective. It is our belief that this is the best process for us to ensure efficient and targeted spending on marketing. Thus, doing our best to provide investors with a reliable and safe path to high growth and profitability.
Our excitement about cosmetics should not cause our investors to forget about our primary business of providing medicinal cannabis to Polish patients. We are working hard on our primary business and the application process, preparing implementation and discussing future products for Project Poland. The discussions with the authorities are going as expected, and we are confident that we are getting closer to obtaining authorization for the distribution of medical cannabis in the market. We are confident in our primary business and anxiously waiting to unlock the great potential for an enormous opportunity for ODI. Our goal is to start operations in the not-so-distant future.
Lastly, I would like to thank our investors for the trust you have in our company. We will continue to work hard building to build shareholder value, and with our strong market position, I feel confident saying that we are on the right path on our future journey.
Derek Simmross
CEO,
For more information on
Derek Simmross, CEO,
E-mail: info@odipharma.com
https://news.cision.com/odi-pharma/r/odi-pharma-ab--publication-of-interim-report-for-the-first-quarter-2021-2022,c3461054
https://mb.cision.com/Main/19043/3461054/1501862.pdf
(c) 2021 Cision. All rights reserved., source